

          -  1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress,
             RR >= 30 times / min, or SaO2 / SpO2 <= 93% in resting state, or arterial partial
             pressure of oxygen (PaO2) /concentration of oxygen (FiO2) <= 300mmHg (1mmHg = 0.133kpa)

          -  2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory
             failure and mechanical ventilation required, or shock, or combined with other organ
             failure required ICU monitoring treatment

          -  3. Severe liver disease (e.g. Child Pugh score >= C, AST > 5 times upper limit)

          -  4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets

          -  5. Patients with definite contraindications in the label of ritonavir

          -  6. Positive serum pregnancy test result for women with childbearing potential at
             screening

          -  7. Using HIV protease inhibitor drugs

          -  8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be
             transferred to another hospital during the study period, patient with multiple basic
             diseases, etc.)
      